Market Overview:
The global biopharmaceutical manufacturing market size reached US$ 411.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 935.0 Billion by 2032, exhibiting a growth rate (CAGR) of 9.3% during 2024-2032. The growing adoption of biologics, innovations in biotechnology and genetic engineering techniques, and increasing incidences of several chronic diseases, such as cancer, autoimmune disorders, and diabetes, are some of the major factors propelling the market.
Report Attribute
|
Key Statistics
|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023
|
US$ 411.8 Billion |
Market Forecast in 2032
|
US$ 935.0 Billion |
Market Growth Rate 2024-2032 |
9.3%
|
Biopharmaceutical manufacturing is the process of producing medical drugs and therapies using living organisms or biological systems. It comprises the utilization of biotechnology, such as cell cultures and genetic engineering, to develop a wide range of pharmaceutical products. It involves multiple stages, including fermentation, cell culture, purification, and formulation, which require stringent quality control and regulatory compliance. It differs from traditional chemical-based methods, as it focuses on producing complex molecules, such as proteins, antibodies, and vaccines. As it provides innovative treatments for various medical conditions, the demand for biopharmaceutical manufacturing is rising across the globe.
At present, the increasing demand for efficient production processes and the adoption of single-use technologies to optimize manufacturing efficiency is influencing the market positively. Moreover, the rising awareness about the importance of biopharmaceuticals in improving healthcare outcomes is strengthening the growth of the market. Apart from this, the growing demand for biosimilars that are highly similar versions of approved biologics and are cost-effective alternatives while maintaining comparable efficacy and safety profiles is offering a favorable market outlook. Additionally, the rising preference for automation to streamline production, reduce human error, and enhance efficiency is offering lucrative growth opportunities to industry investors. Besides this, favorable government initiatives to promote healthcare infrastructure, which is impelling the growth of the market. In addition, the rising demand for advanced biopharmaceutical treatments among the masses worldwide is contributing to the growth of the market.
Biopharmaceutical Manufacturing Market Trends/Drivers:
Rising prevalence of chronic diseases
The rising incidence of several chronic diseases, such as cancer, autoimmune disorders, and diabetes, among the masses across the globe is contributing to the growth of the market. In line with this, there is an increase in the demand for targeted and personalized treatment options among individuals. Moreover, biopharmaceuticals offer precise targeting and fewer side effects as compared to traditional drugs. Apart from this, the rising development and manufacturing of biologics that address specific disease pathways and patient profiles is bolstering the growth of the market. Manufacturers are rapidly advancing their technologies to cater to the rising need for tailored therapies. As a result, healthcare systems are focusing on providing more effective and patient-centric treatment solutions.
Increasing adoption of biologics
The rising popularity of biologics, such as monoclonal antibodies, vaccines, and recombinant proteins due to their high specificity and efficacy in treating various diseases is supporting the growth of the market. Apart from this, they often provide targeted treatment with fewer adverse effects, which makes them a preferred choice among patients and healthcare professionals. In line with this, the growing demand for biopharmaceutical manufacturing due to the rising preference for biologics over traditional small molecule drugs is offering a favorable market outlook. Furthermore, companies are investing in expanding their biomanufacturing capabilities to meet the production needs of these complex therapeutic agents.
Innovations in biotechnology and genetic engineering techniques
Continuous advancements in biotechnology, such as genetic engineering and cell culture techniques, assist in the efficient production of biopharmaceuticals. Innovations in gene editing, protein expression, and cell line development significantly improved the efficiency and yield of biologics manufacturing. In addition, these advancements enable the creation of more complex and diverse biopharmaceutical products, ranging from monoclonal antibodies to gene therapies. Furthermore, innovations in high-throughput screening techniques assist in streamlining the identification of optimal production conditions. Moreover, the integration of synthetic biology principles enables the engineering of cellular pathways to enhance yield and product quality, which is offering a positive market outlook. These innovations not only enhance bioprocess development but also contribute to the production of tailored therapies.
Biopharmaceutical Manufacturing Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global biopharmaceutical manufacturing market report, along with forecasts at the global and regional levels for 2024-2032. Our report has categorized the market based on cell culture and class.
Breakup by Cell Culture:
- Mammalian Cell Culture
- Microbial Cell Culture
Mammalian cell culture represents the largest market segment
The report has provided a detailed breakup and analysis of the market based on the cell culture. This includes mammalian cell culture and microbial cell culture. According to the report, mammalian cell culture represented the largest segment. Mammalian cell culture involves the cultivation of cells derived from mammals, such as humans or animals, in a controlled environment outside their natural habitat. This process serves as a foundation to produce biopharmaceuticals, such as monoclonal antibodies, vaccines, and recombinant proteins. It offers various advantages in terms of its ability to correctly fold and modify complex therapeutic proteins and closely represent human biology. In addition, biopharmaceutical manufacturing relies on advancements in mammalian cell culture techniques, which include optimizing culture media, bioreactor systems, and cell line development. The rising demand for mammalian cell culture due to the increasing need for innovative therapies is propelling the growth of the market.
Breakup by Class:
- Monoclonal Antibodies
- Recombinant Proteins
- Interferon
- Granulocyte Colony-Stimulating Factor (G-CSF)
- Erythropoietin
- Recombinant Human Insulin
- Vaccines
- Human Growth Hormones (HGH)
Monoclonal antibodies account for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the class. This includes monoclonal antibodies, recombinant proteins, interferon, granulocyte colony-stimulating factor (G-CSF), erythropoietin, recombinant human insulin, vaccines, and human growth hormones (HGH). According to the report, monoclonal antibodies represented the largest segment. Monoclonal antibodies are a class of biopharmaceuticals that are designed to target specific proteins or cells in the body. They are produced by cloning a single type of immune cell to create identical copies that generate uniform antibodies. mAbs gained popularity due to their precision in treating various diseases, such as cancer, autoimmune disorders, and infectious diseases. They offer high specificity, reduced side effects, and the ability to modulate the immune response. Apart from this, the rising need for personalized medicine is contributing to the growth of the market. Pharmaceutical companies invest in optimizing biopharmaceutical manufacturing processes to produce these complex molecules at commercial scales.
Breakup by Region:
- North America
- Europe
- Asia Pacific
North America exhibits a clear dominance, accounting for the largest biopharmaceutical manufacturing market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, and Asia Pacific. According to the report, North America accounted for the largest market share.
North America held the biggest market share on account of the improved healthcare infrastructure. In line with this, the rising innovation in pharmaceuticals is bolstering the growth of the market in the region. Moreover, the presence of major pharmaceutical companies and academic research institutions in the region is supporting the growth of the market. Apart from this, favorable regulatory frameworks are contributing to the growth of the market in the region.
Competitive Landscape:
Major players are investing in research and development (R&D) activities to discover and develop new biologic therapies. They are focusing on identifying novel targets, engineering efficient production processes, and enhancing the therapeutic properties of existing drugs. In line with this, companies are working to optimize cell culture, purification, and formulation techniques to increase production efficiency, reduce costs, and ensure consistent product quality. Apart from this, key manufacturers are implementing rigorous quality control measures and adhering to regulatory guidelines to meet stringent manufacturing and validation requirements. Furthermore, companies are investing in expanding production facilities and adopting advanced technologies to accommodate larger volumes.
The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
- AbbVie Inc.
- Amgen Inc.
- Biogen Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Novo Nordisk A/S
- Pfizer Inc.
- Sanofi S.A.
Recent Developments:
- In 2022, Johnson & Johnson and its China-focused partner Legend Biotech Corp (LEGN.O) got the approval from U.S. Food and Drug Administration (FDA) for CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy.
- In January 2022, Amgen and Generate Biomedicines announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.
- In 2021, Sanofi announced an agreement to acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company leveraging its proprietary, clinically validated XTEN® and innovative universal protease-releasable masking technology platform, Pro-XTENTM, to discover and develop transformative T-cell engagers (TCE) and cytokine therapies for patients with cancer.
Biopharmaceutical Manufacturing Market Report Scope:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
Kilo Liters |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
- Cell Culture
- Class
- Region
|
Cell Cultures Covered |
Mammalian Cell Culture, Microbial Cell Culture |
Classes Covered |
Monoclonal Antibodies, Recombinant Proteins, Interferon, Granulocyte Colony-Stimulating Factor (G-CSF), Erythropoietin, Recombinant Human Insulin, Vaccines, Human Growth Hormones (HGH) |
Regions Covered |
Asia Pacific, Europe, North America |
Companies Covered |
AbbVie Inc., Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., etc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Benefits for Stakeholders:
- IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the biopharmaceutical manufacturing market from 2018-2032.
- The research report study provides the latest information on the market drivers, challenges, and opportunities in the global biopharmaceutical manufacturing market.
- The study maps the leading, as well as the fastest-growing, regional markets.
- Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the biopharmaceutical manufacturing industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.